. 2023 Apr 17;20(7):694–713. doi: 10.1038/s41423-023-01019-8

Table 2.

New clinical therapeutic strategies targeting B7x

Target	Platform	Tumor type	Phase
B7x	Monoclonal antibody	Advanced and/or metastatic solid tumors, ovarian, NSCLC, breast, endometrial	I, I/II
B7x	Antibody-drug conjugate	Advanced solid tumors, TNBC, endometrial, ovarian, fallopian tube, peritoneal, cholangiocarcinoma, NSCLC, gallbladder, adenoid cystic	I, I/II
B7x x CD3, 4-1BB	Bispecific antibody	Advanced solid tumors, ovarian, endometrial, breast, uterine, squamous cell, NSCLC	I, I/II

Target

Platform

Tumor type

Phase

B7x

Monoclonal antibody

Advanced and/or metastatic solid tumors, ovarian, NSCLC, breast, endometrial

I, I/II

B7x

Antibody-drug conjugate

Advanced solid tumors, TNBC, endometrial, ovarian, fallopian tube, peritoneal, cholangiocarcinoma, NSCLC, gallbladder, adenoid cystic

I, I/II

B7x

CD3, 4-1BB

Bispecific antibody

Advanced solid tumors, ovarian, endometrial, breast, uterine, squamous cell, NSCLC

I, I/II